Clario Business Intelligence
Reporting and analytics for advancing multicenter imaging
Actionable insights to increase imaging study timely execution
Sponsors and CROs involved in multicenter trials for potential therapies face many challenges related to the imaging operations of their studies. Delays in image acquisition and processing, along with the time and costs associated with patient de-identification of every image prolong timelines and increase study site burden. Clario’s Business Intelligence Suite provides the insights needed in near real-time, allowing study monitors to recognize potential issues quickly and implement process improvements to keep studies on track.
Comprehensive insights into your imaging study are available at-a-glance, meaning that CROs and sponsors can monitor performance and progression of all imaging activities via intuitive, configurable, and easy to digest dashboards. With this level and ease of access into imaging study data, study leaders are empowered with a tool to drive study completion, effectively retrain sites, control costs, and optimize productivity.
Unsurpassed accessibility to operational data
Business Intelligence offers the perfect combination of depth of detail and ease of use. Dashboards provide high-level views of the process, making regular tracking simple while simultaneously allowing for granular views into site activity, cycle times, throughput, and reader performance.
Monitor performance and progression of all imaging activities through intuitive, configurable, and easy to digest dashboards.
- A snapshot view of work load balance to identify potential backlogs in process
- Quickly identify if workload is at steady state according to study life cycle
- Details are provided in table format for additional investigation into the dispersion of cycle times and throughput to identify abnormal levels
- Quickly see the level of missed task driving rework and incremental cost
- Reader productivity
- Are the stages of processing getting completed in committed cycle time
